Does Naltrexone Suppress Appetite? The Science Explained

Naltrexone does influence appetite, but not in the straightforward way most people expect. Rather than switching off hunger the way a full stomach would, naltrexone primarily blunts the pleasure and reward you get from eating, particularly from sweet, fatty, and protein-rich foods. Used alone, this effect is real but inconsistent and rarely produces dramatic weight loss. Paired with bupropion in the combination drug Contrave, though, naltrexone becomes part of a synergy that produces clinically meaningful drops in cravings, food intake, and body weight.

How Naltrexone Changes the Experience of Eating

Naltrexone is an opioid receptor antagonist, which means it blocks the same receptors that respond to painkillers and to your body’s own feel-good chemicals, called endorphins. Those endorphins don’t just manage pain; they also play a major role in making food feel rewarding. When you bite into something rich or sweet and feel a small rush of satisfaction, endorphins acting on opioid receptors in the brain are part of what generates that feeling. Naltrexone dulls that reward signal.

In practice, this shows up as a measurable reduction in how pleasant food tastes. A study testing naltrexone against placebo found that rated food pleasantness dropped significantly while participants were on the drug, but the effect was not uniform across all foods. Sweet, fatty, and high-protein foods were most affected. Total food intake did go down, though the overall reduction compared to placebo wasn’t statistically significant. Where it was significant was in the categories hit hardest on the pleasure scale: fat and protein intake dropped meaningfully.¹

This distinction matters. Naltrexone doesn’t make you feel full sooner or suppress the physiological hunger drive in the way that, say, a GLP-1 drug does. Instead, it makes food less appealing, especially the kinds of food that people tend to overeat. If you reach for chocolate or chips because they feel rewarding, naltrexone weakens that pull. If you’re eating plain rice because you’re genuinely hungry, the effect is less pronounced.

Why Naltrexone Alone Doesn’t Reliably Cause Weight Loss

Despite this effect on food reward, naltrexone by itself has failed to produce consistent or clinically meaningful weight loss when used as a standalone treatment. The reason comes down to how the brain regulates energy balance. Naltrexone doesn’t directly act on the hypothalamic circuits that control hunger and satiety signals. It works on reward pathways, but those reward pathways are only one piece of the appetite puzzle.²

One proposed mechanism for how naltrexone does reduce food consumption involves blocking the action of beta-endorphin at opioid receptors, as well as preventing a specific feedback loop in brain cells called POMC neurons.³ But this indirect action on its own simply isn’t powerful enough to override the body’s many other hunger and energy-regulation systems. Some early studies did report appetite suppression and sustained weight loss in small groups of patients taking naltrexone for opioid addiction, but those findings came from tiny samples and haven’t been replicated at scale.

An early trial in obese men illustrates the muddiness of the picture. Food intake was reduced during the naltrexone week for most participants, but seven of the seventeen subjects experienced nausea and other side effects, making it hard to separate a genuine appetite effect from simply feeling too queasy to eat.⁴ Even among the ten who reported no adverse reactions, seven still ate less, which suggests some real appetite suppression beyond the nausea. But the inconsistency is the story: naltrexone alone nudges appetite in the right direction for many people, without pushing hard enough to reliably move the scale.

How Naltrexone and Bupropion Work Together

The combination of naltrexone and bupropion (sold as Contrave or Mysimba) is where the appetite-suppression story gets more convincing. The two drugs target complementary parts of the same brain circuit. Bupropion stimulates POMC neurons, which are brain cells involved in reducing appetite and increasing energy expenditure. But those POMC neurons have a built-in braking system: when they fire, they release beta-endorphin, which loops back and tells the neurons to quiet down. Naltrexone blocks that brake. By preventing the self-silencing, naltrexone lets the appetite-suppressing signal from bupropion keep going longer and stronger.⁵

The clinical results bear this out. In the COR-II trial, a large phase 3 study, participants taking the naltrexone/bupropion combination lost significantly more weight than those on placebo. At 28 weeks, the drug group lost about 6.5% of their body weight compared to roughly 1.9% for placebo. That effect held through 56 weeks, with the combination group at about 6.4% weight loss versus 1.2% for placebo. Substantially more people in the drug group hit clinically meaningful thresholds of 5%, 10%, and 15% body weight lost.⁶ A systematic review and meta-regression analysis of randomized trials also confirmed that the combination of bupropion with naltrexone produced greater weight loss and waist circumference reduction than bupropion alone, reinforcing naltrexone’s role as a booster rather than a solo player.⁷

What Brain Imaging Reveals About Food Cravings

Brain scanning studies have offered a window into what the combination actually does to food-related brain activity. In a study using functional MRI, researchers showed food images to participants before and after four weeks of treatment with naltrexone/bupropion or placebo. The drug group showed significant changes in brain activation across several regions involved in reward processing and self-control, including the superior frontal cortex, the anterior cingulate cortex, the posterior insula, and the hippocampus. The hypothalamus, a brain region central to hunger regulation, showed lower activation after four weeks of treatment in the drug group compared to baseline, while the placebo group showed no change. The difference between groups was statistically significant.⁸

In plainer terms, the drug appeared to dampen how strongly the brain reacted to images of food. The hypothalamus calmed down, and regions tied to decision-making and impulse control shifted their activity patterns. This aligns with patients’ subjective reports of reduced cravings and less preoccupation with food, particularly calorie-dense food.

Effects on Binge Eating and Specific Cravings

The reward-blunting effect of naltrexone has attracted particular interest for binge-eating disorder, where the drive to eat is heavily tied to emotional regulation and pleasure-seeking rather than physical hunger. A randomized double-blind trial tested naltrexone/bupropion against placebo, with or without behavioral weight-loss therapy, for binge-eating disorder. The results showed clear separation: binge-eating remission rates were about 17.7% for placebo, 31.3% for naltrexone/bupropion alone, 37.1% for behavioral therapy with placebo, and 57.1% for the combination of behavioral therapy and naltrexone/bupropion.⁹ Both the medication and the behavioral therapy independently improved outcomes, but combining them roughly tripled the remission rate compared to placebo.

A separate investigation found that the combination also reduced craving specifically for preferred high-calorie sweet snacks and reduced hunger ratings at six weeks, though these effects had faded by the twelve-week mark.¹⁰ The fading of craving suppression over time is a pattern worth noting; it suggests that the drug may be most useful during an initial window when patients are also building new behavioral habits, rather than as a permanent craving eliminator.

Opioid receptors also regulate hedonic aspects of food in people with other eating disorders. Because naltrexone blocks those receptors, small studies and case reports have explored its potential in purging-type anorexia nervosa and bulimia, where it has shown some ability to reduce binge and purge behaviors.¹¹ This research remains preliminary, but it underscores that naltrexone’s appetite effects are rooted in the reward system, which overlaps with the neural circuits driving disordered eating patterns of many types.

Why Some People Respond Much Better Than Others

Clinical trials of naltrexone/bupropion consistently show a spread of outcomes, with clear “responders” and “non-responders.” A pilot study investigated whether genetic variation might explain part of this spread, focusing on a genetic variant near the dopamine D2 receptor gene called Taq1A (rs1800497). People who carry this variant (called A1+ carriers) have roughly 30 to 40 percent fewer dopamine D2 binding sites in the brain’s reward centers. In the study of 33 subjects, A1+ carriers lost an average of about 5.9% of body weight on the combination drug, compared to about 4.2% for non-carriers. The A1+ group’s weight loss was significantly above a clinically meaningful threshold, while the non-carriers’ was not.¹²

This is a small study and the findings are preliminary, but the logic is interesting. People with fewer dopamine D2 receptors may rely more heavily on opioid-mediated reward from food to compensate, making them more responsive when that opioid reward pathway is blocked. If you’re someone who eats for comfort or pleasure more than for physical hunger, the research suggests you might fall more squarely into the “responder” category, though no genetic test is routinely used to predict this in clinical practice yet.

A separate piece of evidence supports this idea from a different angle. In a study of obese women, naltrexone alone didn’t universally reduce craving intensity across doses. But when researchers looked at participants who scored high on “reward-based eating drive,” those individuals showed a stronger response to the higher naltrexone dose. The drug’s craving-suppression effect was concentrated in people whose eating was most driven by reward and pleasure to begin with.¹³

Metabolic Benefits That Go Beyond Weight

For people with type 2 diabetes, the naltrexone/bupropion combination has shown metabolic improvements that extend beyond the number on the scale. In a trial of overweight and obese patients with type 2 diabetes, those on the combination saw significantly greater reductions in HbA1c (a measure of long-term blood sugar control), along with improvements in triglycerides and HDL cholesterol, compared to placebo.¹⁴

A meta-analysis of randomized trials confirmed these lipid and glucose effects more broadly, finding that bupropion alone or combined with naltrexone significantly reduced fasting glucose, insulin levels, insulin resistance, and triglycerides while raising HDL cholesterol.¹⁵ It’s worth noting that some of these metabolic improvements likely stem from the weight loss itself rather than a direct drug effect on metabolism. Still, for patients managing both obesity and diabetes or prediabetes, the metabolic dividends add a meaningful layer of clinical relevance. An animal study comparing naltrexone/bupropion with liraglutide (a GLP-1 drug) and caloric restriction found that all three improved body weight, blood sugar control, and lipid profiles in diabetic rats, though naltrexone/bupropion was less effective than the other two at promoting the regeneration of insulin-producing beta cells in the pancreas.¹⁶

Nausea, Side Effects, and the Appetite Question They Raise

Nausea is the most frequently reported side effect of naltrexone, and it introduces a nagging question: how much of the observed appetite suppression is genuine craving reduction versus simply feeling too nauseous to eat? The early study of obese men noted above found that seven of the seventeen participants experienced nausea or other side effects during the naltrexone week, and those seven ate less.⁴ But seven of the ten participants who reported no adverse reactions also ate less, suggesting the appetite effect isn’t entirely explained by feeling unwell.

An interesting study probed this further by looking at the cortisol and nausea responses triggered by a single dose of naltrexone. Naltrexone-induced nausea was associated with binge eating tendencies and higher body fat, while naltrexone-induced increases in cortisol (a stress hormone) were associated with greater emotional and restrained eating patterns and lower awareness of internal body signals.¹⁷ The researchers proposed that these acute physiological responses to opioid blockade might serve as biomarkers for how much a person’s eating is driven by hedonic and emotional factors. In other words, the people who react most strongly to naltrexone, even with unpleasant effects like nausea and cortisol spikes, may be the same people whose eating patterns are most entangled with opioid-mediated reward.

Low-Dose Naltrexone and Appetite

You may have heard of low-dose naltrexone (LDN), typically taken at doses between 1.5 and 4.5 milligrams, far below the standard 50 mg dose used for addiction or the 32 mg used in Contrave. LDN has gained a following for conditions ranging from autoimmune diseases to chronic pain, and some users report changes in appetite or cravings. The proposed mechanism is different from full-dose naltrexone: at very low doses, naltrexone briefly blocks opioid receptors and then wears off, which may cause a temporary rebound increase in endorphin production. Proponents argue this rebound recalibrates the reward system over time.

Rigorous evidence for LDN’s effects on appetite specifically is thin. The clinical trials discussed throughout this article used standard or higher doses. If you’re considering LDN for appetite or weight purposes, it’s worth knowing that the research base is almost entirely from full-dose studies and from the naltrexone/bupropion combination. The appetite-suppressing effects demonstrated in published trials cannot be straightforwardly extrapolated to doses that are a fraction of the size.

How Naltrexone Compares to Newer Weight-Loss Drugs

The weight-loss landscape has shifted dramatically with the arrival of GLP-1 receptor agonists like semaglutide and tirzepatide, which typically produce weight reductions of 15% or more in clinical trials. The roughly 6% weight loss seen with naltrexone/bupropion is modest by comparison. But the two classes of drugs work through entirely different mechanisms. GLP-1 drugs slow gastric emptying and act on hypothalamic hunger circuits, producing a powerful sense of fullness and reduced appetite. Naltrexone/bupropion targets the reward and craving side of eating. For people whose overeating is more about food feeling irresistible than about relentless physical hunger, the opioid-blockade approach may be particularly relevant, even if the total weight loss is smaller on paper.

Cost, availability, and side-effect profiles also matter. GLP-1 drugs are injectable (with some oral formulations emerging), expensive, and associated with their own gastrointestinal side effects. Naltrexone/bupropion is an oral pill, has been on the market longer, and is generally less expensive. For some patients, it’s the more practical option, and the metabolic improvements in blood sugar, insulin sensitivity, and cholesterol provide added clinical value regardless of the total pounds lost.